These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9085281)

  • 21. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
    Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
    J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
    [No Abstract]   [Full Text] [Related]  

  • 23. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 111In-octreotide scintigraphy in oncology.
    Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
    Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
    Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
    Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
    Warnet A; Harris AG; Renard E; Martin D; James-Deidier A; Chaumet-Riffaud P
    Neurosurgery; 1997 Oct; 41(4):786-95; discussion 796-7. PubMed ID: 9316039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
    Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
    Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
    Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy.
    Pugnale N; Waridel F; Bouzourène H; Boubaker A; Pugnale M; Gaillard RC; Gomez F
    Eur J Endocrinol; 2003 Mar; 148(3):357-64. PubMed ID: 12611618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
    Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
    Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
    van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
    J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
    Hubina E; Nanzer AM; Hanson MR; Ciccarelli E; Losa M; Gaia D; Papotti M; Terreni MR; Khalaf S; Jordan S; Czirják S; Hanzély Z; Nagy GM; Góth MI; Grossman AB; Korbonits M
    Eur J Endocrinol; 2006 Aug; 155(2):371-9. PubMed ID: 16868153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
    Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
    Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.
    Ferone D; de Herder WW; Pivonello R; Kros JM; van Koetsveld PM; de Jong T; Minuto F; Colao A; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1412-7. PubMed ID: 18211974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.